Company news

Moderna, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Moderna to Present at Upcoming Conferences in December 2024

November 24, 2024

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

November 11, 2024

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

November 7, 2024

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 6, 2024

Moderna to Present at Upcoming Conferences in November 2024

October 30, 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

October 27, 2024

Moderna Named a Top Employer by Science for Tenth Consecutive Year

October 23, 2024

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

October 16, 2024

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

October 2, 2024

Abbas Hussain Joins Moderna's Board of Directors

October 1, 2024

Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

September 29, 2024

Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines

September 29, 2024

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

September 16, 2024

Moderna R&D Day Highlights Progress and Strategic Priorities

September 11, 2024

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

September 9, 2024

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

September 8, 2024

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

September 4, 2024

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1

September 2, 2024

Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

September 1, 2024

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

August 22, 2024

Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1

August 22, 2024

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

August 21, 2024

Moderna to Host Investor Event - R&D Day and Business Updates

August 21, 2024

Moderna and Coursera Launch Free Course on mRNA Technology

August 13, 2024

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

July 31, 2024

David Rubenstein Joins Moderna's Board of Directors

July 22, 2024

Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

July 9, 2024

Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines

July 7, 2024

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

July 1, 2024

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

June 27, 2024

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

June 12, 2024

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

June 9, 2024

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

June 6, 2024

Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

June 5, 2024

Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stag...

June 2, 2024

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

May 30, 2024

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

May 21, 2024

Moderna to Present at Upcoming Conferences in May/June 2024

May 12, 2024

Moderna Announces Update on Investigational RSV Vaccine

May 9, 2024

Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024

Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress

April 24, 2024

Moderna and OpenAI Collaborate To Advance mRNA Medicine

April 23, 2024

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

April 21, 2024

Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

April 16, 2024

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

April 2, 2024

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

March 26, 2024

CARsgen Announced 2023 Annual Results

March 26, 2024

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

March 25, 2024

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024

February 28, 2024

Moderna to Present at Upcoming Investor Conferences in March 2024

February 27, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 63 decks. Every deck is listed under its year.